BusinessMinerva Announces Completion of Bridging Study to Select Improved Formulation of MIN-101 for Use in Phase 3 Trial for the Treatment of Negative Symptoms in Patients With SchizophreniaBy Nasdaq OMXJun 22, 2017, 12:30 PM UTC
BusinessETST and its wholly owned subsidiary, Cannabis Therapeutics, Signs Joint Venture with Smart Medicines GMP for the Development of its Cannabis Cannabinoid-Based Drugs & NutraceuticalsBy Nasdaq OMXFeb 14, 2017, 12:15 PM UTC
BusinessEarth Science Tech, Enters Multi-Billion Dollar Sports Supplement Industry via Joint Venture with Nutrition Specialties and ForzagenBy Nasdaq OMXJan 31, 2017, 12:45 PM UTC
